Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Apr 15, 2023; 15(4): 689-699
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689
Published online Apr 15, 2023. doi: 10.4251/wjgo.v15.i4.689
Clinical characteristic | No. of patients |
Age (yr), median (IQR) | 51 (42-58) |
Sex | |
Male, n (%) | 154 (81.1) |
Etiology | |
Hepatitis B | 144 (75.8) |
Hepatitis C | 4 (2.1) |
Hepatitis B & C | 2 (1.1) |
Non-hepatitis B, non-hepatitis C | 40 (21.0) |
ALT (U/L), median (IQR) | 75 (51-254) |
AST (U/L), median (IQR) | 57 (47-302) |
TBiL (μmol/L), median (IQR) | 20.1 (11.2-31.2) |
AFP (ng/mL), median (IQR) | 205 (19.2-4692) |
Child-Pugh class | |
A | 146 (76.8) |
B | 44 (23.2) |
Portal vein tumor thrombosis | 131 (68.9) |
Extrahepatic metastasis | |
Lung | 64 (33.7) |
Bone | 31 (16.3) |
Peritoneum | 25 (13.1) |
Multiple locations | 15 (7.9) |
BCLC stage | |
C | 190 (100) |
Tumor response | |
Complete response | 0 (0) |
Partial response | 23 (12.1) |
Stable disease | 76 (40.0) |
Progressive disease | 91 (47.9) |
Follow-up time, median (range) | 748 (438-1146) d |
TTP, median (95%CI) | 98 (75-124) d |
OS, median (95%CI) | 376 (340-411) d |
Adverse event | Any grade | Grade 3 | Grade 4 |
Cutaneous toxic effects | 25 (13.2) | 3 (1.6) | 2 (1.1) |
Mucositis | 8 (4.2) | 2 (1.1) | 1 (< 1) |
Rash | 7 (3.7) | 1 (< 1) | 1 (< 1) |
Pruritus | 10 (5.3) | 2 (1.1) | 0 (0) |
Diarrhea | 27 (14.2) | 4 (2.1) | 1 (< 1) |
Elevated transaminases | 35 (18.4) | 10 (5.3) | 2 (1.1) |
Hypothyroidism | 25 (13.2) | 4 (2.1) | 2 (1.1) |
Myocarditis | 3 (1.6) | 1 (< 1) | 2 (1.1) |
Hypoadrenocorticism | 5 (2.6) | 1 (< 1) | 0 (0) |
Proteinuria | 18 (9.5) | 5 (2.6) | 0 (0) |
Overall incidence | 138 (72.6) | 12 (6.3) | 7 (3.7) |
Variable | Univariate analysis | Multivariate analysis | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
OS | ||||
Child-Pugh, class B | 1.446 (1.044-1.547) | 0.039 | 1.321 (1.112-1.711) | 0.021 |
AFP > 400 ng/mL | 1.651 (1.351-1.782) | 0.021 | 1.446 (0.875-1.836) | 0.239 |
PIVKA > 40 mAU/mL | 1.324 (1.023-1.472) | 0.043 | 1.568 (0.411-1.687) | 0.085 |
PVTT, yes | 2.145 (1.897-3.587) | 0.003 | 3.125 (3.015-3.568) | 0.008 |
Extrahepatic metastasis, yes | 1.784 (1.254-2.571) | 0.013 | 2.871 (2.581-3.052) | 0.028 |
Cutaneous toxic effects, yes | 0.741 (0.654-0.968) | 0.025 | 0.845 (0.425-1.751) | 0.129 |
Hypothyroidism, yes | 0.623 (0.487-0.912) | 0.034 | 0.641 (0.489-0.901) | 0.017 |
TTP | ||||
AFP > 400 ng/mL | 1.757 (1.271-1.972) | 0.023 | 1.872 (1.357-2.135) | 0.017 |
PVTT, yes | 2.595 (1.377-3.889) | 0.003 | 2.472 (2.243-2.891) | 0.008 |
Extrahepatic metastasis, yes | 1.536 (1.296-1.765) | 0.031 | 1.489 (1.246-1.574) | 0.012 |
Cutaneous toxic effects, yes | 0.874 (0.621-0.925) | 0.036 | 0.785 (0.358-1.258) | 0.157 |
Hypothyroidism, yes | 0.741 (0.514-0.870) | 0.024 | 0.613 (0.362-0.886) | 0.018 |
- Citation: Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699
- URL: https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i4.689